Michael J. Koren

Michael J. Koren

Cardiology

3901 University Blvd S Ste 221
Jacksonville,, FL 32216

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 67 publications

Evaluation of inactivated and live attenuated, tetravalent dengue vaccine prime-boost strategies in a randomized, open-label, phase I study: implications for understanding immune correlates of protection.

Evaluation of inactivated and live attenuated, tetravalent dengue vaccine prime-boost strategies in a randomized, open-label, phase I study: implications for understanding immune correlates of protection.

Journal: mSphere

Published: August 31, 2026

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role.

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role.

Journal: Journal of lipid research

Published: June 13, 2026

Effect of Evolocumab on Grafts Post-Coronary Artery Bypass Surgery: Post-Hoc Analysis of Newton-CABG CardioLink-5.

Effect of Evolocumab on Grafts Post-Coronary Artery Bypass Surgery: Post-Hoc Analysis of Newton-CABG CardioLink-5.

Journal: JACC. Advances

Published: April 10, 2026

Evaluation of evolocumab on saphenous vein graft patency following coronary artery bypass graft surgery in people living with and without diabetes in the NEWTON-CABG CardioLink-5 trial.

Evaluation of evolocumab on saphenous vein graft patency following coronary artery bypass graft surgery in people living with and without diabetes in the NEWTON-CABG CardioLink-5 trial.

Journal: Diabetes, obesity & metabolism

Published: February 01, 2026

Relationship Between Achieved LDL-C and Saphenous Vein Graft Patency: A Post Hoc Analysis of the NEWTON-CABG CardioLink-5 Study.

Relationship Between Achieved LDL-C and Saphenous Vein Graft Patency: A Post Hoc Analysis of the NEWTON-CABG CardioLink-5 Study.

Journal: European journal of preventive cardiology

Published: December 20, 2025

Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial.

Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial.

Journal: Lancet (London, England)

Published: July 22, 2025

An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: The PURSUIT Randomized Trial.

An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: The PURSUIT Randomized Trial.

Journal: Journal of the American College of Cardiology

Published: February 15, 2025

Phase 1 clinical trial of Hantaan and Puumala virus DNA vaccines delivered by needle-free injection.

Phase 1 clinical trial of Hantaan and Puumala virus DNA vaccines delivered by needle-free injection.

Journal: NPJ vaccines

Published: May 20, 2024

Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial.

Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial.

Journal: JAMA

Published: April 08, 2024

An "Inclisiran First" Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease.

An "Inclisiran First" Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease.

Journal: Journal of the American College of Cardiology

Published: February 22, 2024

Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial.

Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial.

Journal: The Lancet. Infectious diseases

Published: December 13, 2023

A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults†.

A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults†.

Journal: Journal of travel medicine

Published: October 12, 2023

Showing 1-12 of 67

Last Updated: 09/26/2026